Hematological Malignancies In the News
Now celebrating its 10th year, the Caltech and City of Hope Biomedical Research Initiative continues to change the future of science and medicine.
City of Hope, TGen announce letter of intent to build cell therapy manufacturing facility in Phoenix. The move would enable the organizations to meet a demand for clinical cell therapies that is expected to grow 42 percent annually over the next decade.
City of Hope is now enrolling patients in a phase 1 trial evaluating the safety and efficacy of CAR T cell therapy in patients with HER2+ breast cancer that has metastasized to the brain.
A new City of Hope chimeric antigen receptor (CAR) T cell trial – the first to focus on HER2-postive breast cancer patients with brain metastases – is now enrolling potential participants.
Women with HER2-positive breast cancer that has spread to the brain need more treatment options, and City of Hope and Mustang Bio Inc. are meeting that challenge. The immunotherapy trial is the first to deliver CAR T cells directly to the brain of HER2-positive breast cancer patients with brain metastases.
Harnessing the power of CAR T cells
The California Institute for Regenerative Medicine today awarded City of Hope’s Xiuli Wang, Ph.D., $3.8 million to develop CAR T cells that can target and kill HIV-infected cells. The treatment will also use the cytomegalovirus vaccine to stimulate the immune system to proliferate and maintain the CAR T cells.
The California Institute for Regenerative Medicine has awarded City of Hope’s Xiuli Wang, Ph.D., $3.8 million to develop chimeric antigen receptor (CAR) T cells that can target and kill HIV-infected cells.
Before her bone marrow transplant at City of Hope, Cierra Jackson's future was uncertain thanks to her sickle cell disease. Now, she's pushing forward with her dreams and helping others with the disease.
City of Hope’s Stephen J. Forman, M.D., is now an official member of the Parker Institute for Cancer Immunotherapy.
Since 2013, City of Hope researcher Saul Priceman, Ph.D., and his team have developed one of most comprehensive CAR T programs in the nation.
By moving all of the clinical research services and staff to one place, we are enabling many of our patients to complete all of their clinical trial appointments in a single visit at a single location. The Briskin Center includes infusion areas, nursing stations, exam and procedure rooms, onsite pharmacy and lab services, a dedicated registration site and outdoor seating for patients and their families.
City of Hope's Linda Malkas, Ph.D., never envisioned a life in cancer research for herself. She wanted to be an astronaut, but after attending engineering school, she abandoned her interest in going into space.
These three City of Hope physicians have dramatically different backgrounds, but they share a devotion to helping people and saving lives and now they share in the generosity of longtime City of Hope philanthropists Norman and Melinda Payson. Vijay Trisal, M.D., Jeffrey Weitzel, M.D., and John Chan, M.D., were recent invested through gifts made from the Payson family.
The Dr. Norman and Melinda Payson Professorships recognize City of Hope clinicians and researchers who have contributed greatly to biomedical research.
After many complications, City of Hope lymphoma patient Lucy found renewed hope after an immunotherapy clinical trial.
City of Hope’s CAR T research and treatment team is now an official member of the Parker Institute for Cancer Immunotherapy.
City of Hope’s John Zaia, M.D., will lead the development of the phase 1 clinical trial for glioblastoma patients, which would genetically alter blood stem cells to better tolerate chemotherapy.
Steven T. Rosen, M.D., just marked his fourth year at City of Hope as provost and chief scientific officer. On the occasion of his first four years at City of Hope and the recent five-year renewal of a National Cancer Institute grant, we sat down with Rosen to reflect on his time at City of Hope.
City of Hope researchers may have discovered a more effective treatment for patients with chronic myelogenous leukemia (CML) according to a study published today in Nature Medicine.
Joseph Alvarnas, M.D. describes himself as a storyteller, and for the City of Hope hematologist/oncologist, stories play a key role in how he sees the medical profession, his role in it, and even why he became a physician in the first place.
FDA approves tisagenlecleucel (commercial name Kymriah) CAR T cell therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Cheryl Wiers knew her cancer diagnosis happened for a reason, and for her, that reason could be her participation in a clinical trial using what is arguably the most promising cancer treatment — CAR T cell therapy.
CAR T Cells Save Chuck Fata's Life
City of Hope’s annual Kids 4 Hope program, in partnership with Albertsons Companies Foundation, Vons Foundation and Pavilions Foundation, has raised over $1 million to support research and treatment for pediatric cancers.